Drug control of biofilm dispersion due to regulation of the activity of bacterial cyclic guanosine monophosphate (part 1)

• Main Author: А.Е. Abaturov
• Format: Article
• Language: English
• Published: Publishing House Zaslavsky 2020-02-01
• Series: Zdorovʹe Rebenka
• Subjects: bacterial biofilms; dispersion; c-di-gmp; antibiofilm therapy; review
• Online Access: http://childshealth.zaslavsky.com.ua/article/view/196759

The infectious process caused by pathogenic bacteria can be accompanied by the formation of a biofilm, which determines the safety of bacteria and a decrease in the effectiveness of antibacterial agents. The development of drugs that contribute to the dispersion of bacterial biofilms is one of the most important therapeutic areas, which help solve the problem of treating bacterial infections caused by microorganisms that are resistant to antibacterial agents. One of the target bacterial molecules involved in biofilm formation, which can be subjected to drug regulation, is a nucleotide secondary messenger molecule — cyclic dinucleotide guanosine monophosphate (c-di-GMP). Drug suppression of the level of intra-bacterial concentration of the messenger molecule of c-di-GMP or blocking its activity helps prevent the formation of bacterial biofilm and leads to its destruction, which is accompanied by an increase in the level of effectiveness of treatment of bacterial infections. A decrease in the level of intra-bacterial concentration of c-di-GMP can be achieved by inhibiting the synthesis processes due to: 1) suppression of diguanylate cyclase activity; 2) restriction on the availability of substrates required for the synthesis of c-di-GMP; 3) increased degradation of c-di-GMP molecule due to activation of phosphodiesterase activity. The treatment of infectious diseases, which are accompanied by the formation of biofilms, requires the medical induction of the dispersion of bacteria from biofilms and the use of targeted antibiotic drugs that cause the death of bacteria released from biofilms. The use of c-di-GMP analogues, which disrupt the functioning of native c-di-GMP, and the blocking of targeted receptors and other molecular structures can also lead to the dispersion of bacterial biofilm. Medicines that modulate the activity of c-di-GMP will increase the effectiveness of the antibacterial treatment of bacterial infections, which are accompanied by the formation of biofilms.